Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced vs standard fluence photodynamic therapy with intravitreal triamcinolone for AMD-related CNV
2005-000776-41Phase 4Completed
- Sponsor
- Department of Ophthalmology
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of verteporfin and triamcinolone acetonide in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by Department of Ophthalmology. Started May 2005; status: completed.
02
Drugs
verteporfintriamcinolone acetonide
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-000776-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000776-41.